KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.

Shinichiro Suzuki Kimio YonesakaTakeshi TeramuraToshiyuki TakeharaRyoji KatoHitomi SakaiKoji Haratani Junko Tanizaki Hiasto Kawakami Hidetoshi HayashiKazuko SakaiKazuto NishioKazuhiko Nakagawa

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

MET amplification leads to the development of resistance to KRAS G12C inhibitors in NSCLC. Dual blockade of MET and KRAS G12C could be a treatment option for MET-amplified, KRAS G12C-mutated NSCLC.

Keyphrases

wild type
tyrosine kinase
small cell lung cancer
single cell
mesenchymal stem cells
combination therapy